Mineralys Therapeutics, Inc. MLYS Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s other commercial liabilities?
- Mineralys Therapeutics, Inc. (MLYS) reported other commercial liabilities of $13.6M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s other commercial liabilities changed year-over-year?
- Mineralys Therapeutics, Inc.'s other commercial liabilities increased by 4.5% year-over-year, from $13.01M to $13.6M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s other commercial liabilities?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s other commercial liabilities has grown at a 28.6% compound annual growth rate (CAGR), from $6.16M to $13.1M.